BeOne Medicines (ONC) Accumulated Expenses (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Accumulated Expenses of $1.1 billion for Q1 2026, up 55.93% year-over-year from $692.2 million in Q1 2025, and down 2.69% quarter-over-quarter from $1.1 billion in Q4 2025.
BeOne Medicines (ONC) Accumulated Expenses (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Accumulated Expenses for 12 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 55.93% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 55.93% YoY), while the FY2025 annual figure was $1.1 billion, up 38.0% from the prior year.
- Accumulated Expenses declined to $1.1 billion in Q1 2026 per ONC's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.1 billion in Q4 2025 and bottomed at $386.0 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $674.7 million across 5 years, with a median of $646.5 million in 2024.
- Annual changes were most pronounced in 2023 — Accumulated Expenses rose 0.17% — and 2026, when it jumped 55.93%.
- BeOne Medicines' Accumulated Expenses stood at $619.5 million in 2022, then gained by 11.99% to $693.7 million in 2023, then increased by 15.85% to $803.7 million in 2024, then jumped by 38.0% to $1.1 billion in 2025, then retreated by 2.69% to $1.1 billion in 2026.
- Business Quant data shows ONC's Accumulated Expenses at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Bn |
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.11 Bn |
| Sep 30, 2025 | 1.00 Bn |
| Jun 30, 2025 | 908.88 Mn |
| Mar 31, 2025 | 692.18 Mn |
| Dec 31, 2024 | 803.71 Mn |
| Sep 30, 2024 | 717.34 Mn |
| Jun 30, 2024 | 646.54 Mn |
| Mar 31, 2024 | 569.44 Mn |
| Dec 31, 2023 | 693.73 Mn |
| Sep 30, 2023 | 505.82 Mn |
| Jun 30, 2023 | 454.95 Mn |
| Mar 31, 2023 | 417.92 Mn |
| Dec 31, 2022 | 619.49 Mn |
| Sep 30, 2022 | 410.26 Mn |
| Jun 30, 2022 | 454.18 Mn |
| Mar 31, 2022 | 385.98 Mn |
| Dec 31, 2021 | 558.06 Mn |
| Sep 30, 2021 | 389.87 Mn |